Medical network - on February 24, after the company, after seed Huang, and there's a listed companies selling exclusive proprietary Chinese medicine to raise prices. Recently, ma yinglong announcement, according to increase the company's leading product ma yinglong musk hemorrhoids ointment (10 grams) supply, price increase of 18%.
Journalists access to relevant data, found that the three drug firms have to raise prices of products are the company's leading products, and has good grades in the retail market, has the high competitiveness in the similar products. Look from the annual report data, the leading product prices, corporate performance have been varying degrees of ascension.
Analysis of the personage inside course of study says, exclusive varieties because of a lack of competition, there is a lot of space on the pricing. Go health channels will have price pressure, and retail terminal pressure is relatively small. Drug firms price behavior seems to be helpless, but hidden behind the deep strategy layout.
Exclusive proprietary Chinese medicine prices are retail market of the seller
Ma yinglong the raising price of product is exclusive proprietary Chinese medicine ma yinglong musk hemorrhoids ointment (10 grams), the product is OTC varieties of b class, enter the medicine and medical insurance directory.
According to m, according to data from the network ma yinglong musk hemorrhoids ointment in 2015 cities in China retail pharmacies proprietary Chinese medicine hemorrhoids medicine pattern ranked first, sales of nearly 250 million yuan. Public medical institutions in China traditional pattern of hemorrhoids medicine product TOP20 ranks third in the combined sales of nearly 140 million yuan.
Compound glue mucilage is exclusive proprietary Chinese medicine, the company is OTC b varieties, entered the medical insurance directory.
According to m, according to data from the network compound glue mucilage urban retail pharmacies proprietary Chinese medicine in China in 2015, ranked second in the blood tonic medicine pattern, sales of more than 900 million yuan; Public medical institutions in China traditional pattern of blood drug product TOP20 ranks third in the total sales of more than 300 million yuan.
Seed Huang includes capsule and tablet, in addition, the compound seed Huang buccal tablet, compound seed Huang ointment is zhangzhou seed Huang pharmaceutical exclusive proprietary Chinese medicine, in addition to slice seed Huang capsule, the above three products are OTC class a product.
According to m Intranet data, 2015 pieces of Huang in China ranked first in the retail pharmacy proprietary Chinese medicine hepatitis medical pattern of cities, the sales of nearly 470 million yuan. Compound piece son Huang ointment in China urban retail pharmacies pattern of proprietary Chinese medicine dermatology other drugs ranked first, sales of more than 90 million yuan. From the point of sales, the four main products sales positions are the retail market.
The leading product prices rising corporate earnings
Compared with the company and seed Huang, ma yinglong number of price increase is not so much. According to media reports, in addition to the most recent price increase, ma yinglong also mentioned the price at the end of 2007, 15%, supply settlement prices rose 8.70% in June, 2009... From ma yinglong revenue and net profit in the past ten years of trends, a few times after the price performance has the corresponding ascension, leading product prices can really drive the yields rose.
From ma yinglong product information in the performance in terms of the proportion of medicine circulation and anorectal hemorrhoids products are the company's main plate. Anorectal hemorrhoids cure, by contrast, product cost ratio is low, gross margin is more than 70%. Ma yinglong mentioned in this notice, the price, the product of 2017 annual sales revenue and gross margin is expected to improve accordingly.
According to m Intranet mids, according to data from the database of ma yinglong production musk hemorrhoids medicine in addition to ma yinglong haemorrhoid creams, and elm tree may clear heat, Jin Xuan hemorrhoid hemostatic capsule fumigation dispersion, musk hemorrhoids suppository, the above products are exclusive varieties, and there are varieties of non-exclusive hemorrhoids inflammation disappear.
According to incomplete statistics, since 2006, the company to raise prices have more than 10 times, the most recent price increase is on November 17, 2016. In recent ten years, the company operating income and net profit growth rapidly.
From the company's main products in the performance in terms of the proportion of gelatin series product occupies the absolute dominant position, income ratio is very high, gross margin is more than 75%, gelatin series products are the lifeblood of a relationship between the enterprise, a.
The company over the years of the mentioned price products including gelatin, compound glue mucilage and peach blossom gelatin cake. In China's urban retail pharmacies proprietary Chinese medicine blood tonic medicine pattern TOP1 product is donkey-hide gelatin, 2015 market share reached 76.81%, the product competition more than 30 enterprises, the company accounted for more than 57%. Peach blossom kyi gelatin cake also is doing better in health care products market reputation, market share is gradually enlarged.
In the past decade, wang Huang also increases ten times. There are media reports that piece of wang Huang lozenge from 130 yuan in 2005 rose to 500 yuan / / grain, the price close to the quadruple. In recent ten years, slice Huang trend of operating income and net profit rose too rapidly.
Seed Huang series products including the pills Huang capsule and tablet, compound seed Huang buccal tablet, compound seed Huang ointment, compound piece of seed Huang hemorrhoids ointment, these products are the company's exclusive varieties, total combined share of the top 10 the products share more than seventy percent, the price of the products of the company's performance is holding a launch the influence of the body.
Frequently price exclusive proprietary Chinese medicine retail market will become the new field?
In recent years, Chinese medicine raw materials prices generally rise, not only bring pressure to the proprietary Chinese medicine production enterprises, also let them have a reason to raise prices, media reports pointed out that the three companies the cause price increases, this is many times.
M network reporter on the analysis of the above is price products found several features: a best-selling products are varieties, there has been a very good reputation in the market and support; Second, most of the products as the exclusive varieties, lack of competition, it is not easy to find alternative; Three, the product has a good sales in the retail market, and even some products main market is the retail terminal.
The new health care reform, a series of related policies in the ultimate goal is to solve problems in public medical care cost. Among them, the bidding, two votes, medicare payments are especially focused on lower drug prices and drug firms terminal products in medical institution, the pressure will only become more and more big. As the medicine apart, the prescription outflow, pharmacy custody measures such as promotion and gradually implemented, pharmaceutical production enterprise began to look to the retail market, attention is also rising.
The promulgation of the law of traditional Chinese medicine, to the proprietary Chinese medicine production enterprises more encouragement, also let citizens for TCM products have more trust. Especially some exclusive varieties, good reputation, good curative effect in the retail market potential is inestimable. In the future, will have more hands exclusive varieties, best-selling drug companies in the retail market is like in overweight, the new battleground can give drug firms more unexpected harvest? We will continue to follow for you. |
